11 – 20 of 57
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following IV administration in haemophilia patients.
(
- Contribution to journal › Article
-
Mark
Joint protection in haemophilia
(
- Contribution to journal › Article
-
Mark
Monitoring rFVIIa 90 μg kg(-1) dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
(
- Contribution to journal › Article
-
Mark
Redistribution and Hemostatic Action of Recombinant Activated Factor VII Associated with Platelets
(
- Contribution to journal › Article
-
Mark
First 20 years with recombinant FVIIa (NovoSeven).
(
- Contribution to journal › Article
-
Mark
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
(
- Contribution to journal › Article
- 2010
-
Mark
10th anniversary of the haemophilia/haemostasis Novo Nordisk symposium
(
- Chapter in Book/Report/Conference proceeding › Preface to conference proceeding
-
Mark
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
(
- Contribution to journal › Article
-
Mark
rFVIIa transported from the blood stream into tissues is functionally active
(
- Contribution to journal › Letter
-
Mark
Reply to 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors' (Haemophilia 2009; 15: 3-10).
(
- Contribution to journal › Article